Furthermore, combining PCSK9 inhibitors with OVA-II peptide vaccines can achieve better anti-tumor effects, providing evidence for applying PCSK9 inhibition as a promising immunoregulatory therapeutic strategy for cancer treatment. The gene discussed is PCSK9; the disease is neoplasm.